Home > Boards > US OTC > Biotechs >

Mateon Therapeutics Inc. (MATN)

MATN RSS Feed
Add MATN Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 3/27/2020 3:47:48 PM - Followers: 6 - Board type: Free - Posts Today: 0

 

Investor Overview

http://investor.mateon.com/
Press Releases
Mar 02, 2020
https://www.oncotelic.com/management/
https://www.oncotelic.com/oxi4503/
https://www.oncotelic.com/collaboration-opportunities/



 

Collaboration Opportunities

 

Oncotelic is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs.
We have a history of successful partnerships and welcome new collaboration and licensing opportunities.

Interested parties may contact:
Chulho Park PhD,  Chief Technology Officer
Oncotelic Inc.
29397 Agoura Rd., Suite 107
Agoura Hills, CA 91301
bd@oncotelic.com
(650) 635-7000

Partners

The Christie Hospital NHS Foundation Trust

Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by
Cancer Research UK (CRUK) along with additional academic partners.
Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust
and coordinated by the Manchester Academic Health Science Centre,

Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust,
and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).
This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib
alone for the treatment of advanced recurrent ovarian cancer.
We are providing CA4P for use in this trial.

University of Kentucky, Markey Cancer Center

Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297).
The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors.

In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of
CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination.  
The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data.
Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.
 

We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable
vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide.

We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.

Our common stock is traded on the OTCQB Market under the symbol “MATN”.

We are headquartered in Agoura Hills, California

https://www.oncotelic.com/pointr-data/
 

EdgePoint

About EdgePoint Inc.

https://www.oncotelic.com/pointr-data/

EdgePoint AI was established in order to advance the company’s revolutionary cluster-computer platform for AI that processes machine learning
models at a fraction of the power and budget of mainstream computing in pharmaceutical manufacturing.
The company’s technology solution “TrustPoint” provides an AI computing platform for pharmaceutical and healthcare verticals
including blockchain support for manufacturing where data integrity and security are of utmost importance.

EdgePoint is composed of a team of executives with pharmaceutical drug development, GMP manufacturing and deep AI knowledge.

The team includes Steven King who was the former CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ) and its wholly-owned
contract biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its
lead compound through Phase 3 development, while growing revenues to over $55 million;
Seasoned executive, Saran Saund who has been founder, CEO and GM at several startups and public companies for which he returned
significant value to shareholders in his startups and chief technology officer; Burcak Beser who has been founder and
CTO of several successful private and public companies with over 144 patents during his career; and Lisa Stepp with broad experience in
executive leadership across geographies and in all aspects of drug development and program management.
The core technology platform for EdgePoint AI came from PointR -which was acquired by Mateon in Nov 2019. Examples of PointR capabilities are shown below.



http://oncotelic.com/wp-content/uploads/LosAngelesBusinessJournal2018-05-21.pdf
Health Care: Drug Developer Adds Digital Monitor



TWO YEAR CHART: NASDAQ

 
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.


 



 

MATN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#80  Sticky Note Mateon Report Positive Results for Multiple COVID-19 Drug Candidates davidsson10 03/25/20 08:06:19 AM
#112   partnership ????? 'Mateon Therapeutics Inc. (MATN)' mick 03/27/20 03:47:48 PM
#111   More dilution... Smh S3lfMade 03/27/20 10:34:55 AM
#110   mick...whats holding this back ? stockaudit 03/27/20 07:09:24 AM
#109   https://www.otcmarkets.com/stock/MATN/security mick 03/26/20 01:19:01 PM
#108   i agree my friend, SS, mick 03/26/20 01:17:10 PM
#107   Careful here .. massive dilution yesterday S3lfMade 03/26/20 09:33:54 AM
#106   Love the SS KILLERMIKE 03/26/20 09:01:37 AM
#105   https://www.forbes.com/sites/cognitiveworld/2020/03/19/how-artificial-intelligen KILLERMIKE 03/25/20 10:05:22 PM
#104   WOW READ, Current Price ?0.130 USD,1-Year Forecast mick 03/25/20 01:22:15 PM
#103   Mateon Therapeutics Inc (MATN) mick 03/25/20 01:19:06 PM
#102   DONE MY FRIEND,'Mateon Therapeutics Inc. (MATN)' mick 03/25/20 01:07:39 PM
#101   https://walletinvestor.com/stock-forecast/MATN-stock-prediction ================================= mick 03/25/20 01:05:17 PM
#100   www.stockscores.com/chart.asp?TickerSymbol=MATN&TimeRange=1825&Interval=w mick 03/25/20 01:04:15 PM
#99   www.stockscores.com/chart.asp?TickerSymbol=MATN&TimeRange=180&Interval=d&Volume=1 mick 03/25/20 01:03:07 PM
#98   http://www.barchart.com/quotes/stocks/MATN mick 03/25/20 01:02:39 PM
#97   www.stockta.com/cgi-bin/candle.pl?cobrand=&symb=MATN&size=analysis&support=0.00,1 mick 03/25/20 01:01:57 PM
#96   4-MOS- www.stockscores.com/chart.asp?TickerSymbol=MATN&TimeRange=90&Inter mick 03/25/20 01:00:13 PM
#95   10yr, Chart NASDAQ mick 03/25/20 12:59:18 PM
#94   TWO YEAR CHART: NASDAQ mick 03/25/20 12:55:49 PM
#93   Can we get this post stickied? Caveat Emptor 03/25/20 12:51:03 PM
#92   Mateon Report Positive Results for Multiple COVID-19 Drug Candidates mick 03/25/20 12:44:10 PM
#91   Mateon Partners With Meridian IT To Fast Track mick 03/25/20 12:42:00 PM
#90   https://www.barchart.com/stocks/quotes/MATN/news mick 03/25/20 12:28:32 PM
#89   https://www.barchart.com/stocks/quotes/MATN/price-history/historical mick 03/25/20 12:27:39 PM
#88   https://www.barchart.com/stocks/quotes/MATN/cheat-sheet mick 03/25/20 12:27:02 PM
#87   https://www.barchart.com/stocks/quotes/MATN/technical-analysis mick 03/25/20 12:26:36 PM
#86   https://www.barchart.com/stocks/quotes/MATN/technical-chart mick 03/25/20 12:26:00 PM
#85   thank you for updating, $matn mick 03/25/20 12:24:31 PM
#84   Current Report Filing (8-k) Edgar (US Regulatory) - mick 03/25/20 12:21:28 PM
#83   Current Report Filing (8-k) Edgar (US Regulatory) - mick 03/25/20 12:21:21 PM
#82   Geez Awl416 03/25/20 12:17:43 PM
#81   on watch here Jongkey 03/25/20 12:17:06 PM
#80   Mateon Report Positive Results for Multiple COVID-19 Drug Candidates davidsson10 03/25/20 08:06:19 AM
#79   I meant good day today shurtha2000 03/18/20 08:28:09 AM
#78   going to be a good today shurtha2000 03/18/20 08:27:29 AM
#77   8 day-50 day-200 day-https://www.barchart.com/stocks/quotes/MATN/technical-chart mick 03/15/20 12:51:52 PM
#76   www.stockscores.com/chart.asp?TickerSymbol=MATN&TiYDYnge=180&Interval=d&V mick 03/05/20 01:41:00 PM
#75   SRNE Try some going to move shurtha2000 03/05/20 10:26:34 AM
#74   the spreading of coronavirus not slowing down. $MATN mick 03/05/20 10:18:28 AM
#73   COVID-19 CORONAVIRUS OUTBREAK,Coronavirus Cases:96,949,Deaths:3,308 mick 03/05/20 10:12:57 AM
#72   do have news item my friend ????? $IBIO mick 03/05/20 09:14:51 AM
#71   IBIO moving again on china news shurtha2000 03/05/20 08:45:36 AM
#70   www.stockscores.com/chart.asp?TickerSymbol=MATN&TimeRange=90&Interval=d&V mick 03/04/20 11:31:47 PM
#69   maybe IBIO buyout ????? for $MATN mick 03/04/20 03:16:10 PM
#68   Reading, you are right on my friend, IBIO mick 03/04/20 03:14:50 PM
#67   $MATN,OTC DISCLOSURE & NEWS SERVICE,Mateon Provides Update on mick 03/04/20 03:13:02 PM
#66   this company ????? $MATN mick 03/04/20 03:09:40 PM
#65   $MATN, thank you. interesting company, good mgmt too. mick 03/04/20 03:08:34 PM
#64   Nice Job on the Board shurtha2000 03/04/20 03:05:12 PM
#63   CONTACT DETAILS/'Mateon Therapeutics Inc. (MATN)' mick 03/04/20 02:26:49 PM
PostSubject